Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicin

Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patients with a type of ​autoimmune disease in a mid-stage study.

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest dataset reported for litifilimab in CLE and further support its potential to achieve rapid and durable improvements in skin disease activity. In the study, participants treated with litifilimab in the double-blind, placebo-controlled period showed continued clinical improvements in skin disease activity through Week 52. Notably, participants who switched from placebo to litifilimab treatment at Week 24 experienced a rapid onset of treatment effect as early as four weeks.

Biogen Inc. (NASDAQ: BIIB - Get Free Report) shares hit a new 52-week high on Monday. The company traded as high as $229.62 and last traded at $228.8480, with a volume of 297708 shares. The stock had previously closed at $227.60. Analyst Upgrades and Downgrades Several analysts have issued reports on BIIB shares. Zacks Research upgraded

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Biogen (NASDAQ: BIIB - Get Free Report) and Mesoblast (NASDAQ: MESO - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings. Insider and Institutional Ownership 87.9% of Biogen shares are held

CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the  Clinical Journal of the American Society of Nephrology (CJASN). The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Society of Paediatric Nephrology (ESPN).

Corient Private Wealth LP raised its stake in shares of Biogen Inc. (NASDAQ: BIIB) by 14.7% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 42,397 shares of the biotechnology company's stock after acquiring an additional 5,445 shares during the period. Corient Private Wealth LP's holdings

Biogen (NASDAQ: BIIB - Get Free Report) and Fulcrum Therapeutics (NASDAQ: FULC - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Earnings and Valuation This table compares Biogen and Fulcrum